Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.

doi:10.1016/j.humpath.2015.06.023

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.

Human pathology - 1 Nov 2015

Uguen Arnaud, Guéguen Paul, Legoupil Delphine, Bouvier Stéphanie, Costa Sebastian, Duigou Sandrine, Lemasson Gilles, Ledé Françoise, Sassolas Bruno, Talagas Matthieu, Férec Claude, Le Maréchal Cédric, De Braekeleer Marc, Marcorelles Pascale

Abstract excerpt

NRAS and BRAF mutational status has become mandatory to treat patients with metastatic melanomas. Mutation-specific immunohistochemistry (IHC) can help analyze challenging tumor samples. We report our experience integrating NRASQ61R (SP174) and BRAFV600E (VE1) IHC in routine practice in a cancer molecular genetic platform. All samples screened for BRAF and NRAS mutations during the year 2014 were analyzed by IHC...

Topics

Adult
Aged
Aged, 80 and over
Early Detection of Cancer
Female
GTP Phosphohydrolases
High-Throughput Nucleotide Sequencing
Humans
Immunohistochemistry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Male

Melanoma

Membrane Proteins

Middle Aged

Mutation

Proto-Oncogene Proteins B-raf

Skin Neoplasms

Source

Open in PubMed

Identifiers

PMID: 26297254
DOI: 10.1016/j.humpath.2015.06.023

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-26297254-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.PMID 26297254Read ↗

Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in MelanomaSemantic proximity Read ↗

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.Semantic proximity Read ↗

Effects of BRAF V600E and NRAS mutational status on the progression‑free survival and clinicopathological characteristics of patients with melanomaSemantic proximity Read ↗

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.Semantic proximity Read ↗

Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.Semantic proximity Read ↗

Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma.Semantic proximity Read ↗

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.Semantic proximity Read ↗

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.Semantic proximity Read ↗

A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.Semantic proximity Read ↗

Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.Semantic proximity Read ↗

Improving care of melanoma patients through efficient, integrated cellular-molecular pathology workflows using tissue samples with low tumour nuclear content.Semantic proximity Read ↗

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.